长春瑞滨联合贝伐单抗治疗非小细胞肺癌的临床分析

目的分析长春瑞滨联合贝伐单抗治疗非小细胞肺癌(NSCLC)的临床疗效及生存情况。 方法选择我院2017年4月至2020年3月接诊的42例NSCLC患者作为观察对象，依据临床治疗方案将患者分为观察组22例和对照组20例，给予对照组患者顺铂+长春瑞滨治疗，观察组患者在对照组基础上联合贝伐单抗治疗。评估两组患者治疗2周后的临床疗效、血清肿瘤因子血清血管生成素样蛋白2(ANGPTL2)、抗菌肽人类阳离子抗菌蛋白18(hCAP18)及血清癌胚抗原(CEA)]水平、药物不良反应及12个月随访后的生存情况。 结果观察组疾病控制率(81.82%)高于对照组(60.00%)，差异有统计学意义(P<0.05)；治疗后，两组患者的血清hCAP18、CEA及ANGPTL2水平均低于治疗前，且观察组较对照组更低，差异有统计学意义(P<0.05)；观察组1年生存率(77.27%)高于对照组(45.00%)，差异具有统计学意义(P<0.05)；两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。 结论给予NSCLC患者长春瑞滨联合贝伐单抗治疗，有助于改善患者的临床疗效，提高患者的疾病控制率，降低患者的血清hCAP18、CEA及ANGPTL2水平，提高患者的1年生存率，且安全性较好。

Clinical analysis of vinorereabine combined with bevacizumab in non-small cell cancer patients

ObjectiveTo analyze the clinical efficacy and survival of vinorereabine combined with bevacizumab for non-small cell lung cancer (NSCLC). Methods42 cases with NSCLC treated by our hospital from April 2017 to March 2020 were collected for this study. According to the clinical treatment, all of the cases were divided into observation group (22 cases) and control group (20 cases). In control group, patient with cisplatin plus vinorereabine. In observation group, patients treated combined with bevacizumab on a control basis. The clinical efficacy of two groups was evaluated after 2 weeks of treatment, serum tumor factors serum angiopoietin-like protein 2 (ANGPTL2), antimicrobial peptide human cationic antimicrobial protein 18 (hCAP18) and serum carcincoembryonic antigen (CEA)] levels, adverse drug effects, and survival after 12-month follow-up. ResultsIn observation group, the disease control rate was higher than control group (P<0.05). After treatment, the serum hCAP18, CEA and ANGPTL2 levels were lower than before, and the observation group was lower than control group(P<0.05). The 1-year survival rate, observation group was higher than control group (P<0.05). There was no significant difference in the incidence of adverse reactions in two groups(P>0.05). ConclusionVinorereabine combined with bevacizumab in NSCLC patients, to improve the clinical efficacy of patients, improve the disease control rate of patients, reduce the serum levels of hCAP18, CEA and ANGPTL2 in patients, improve the 1-year survival rate of patients, and better safety.